David has over 30 years of experience providing a wide range of corporate advisory services to clients in healthcare and related industries. Clients have included life sciences companies Novartis, Boehringer Ingelheim, Endo, Par Pharmaceutical, Lannett, Juno Pharmaceuticals, Lupin, JHP Pharmaceuticals, G&W Laboratories, Pharmaceutical services providers Cardinal Health, National Prescription Administrators and BLP Group Companies, and healthcare technology and IT start-ups including Metagreen, Simstar Internet Solutions, oncology.com, and Consumer2Patient. David has also worked with development-stage companies, including Ethicann Pharmaceuticals, MesaGreen Pharmaceuticals, Silverpeak Life Sciences, and Interamerican Life Sciences. He has advised venture capital and private equity-backed companies to maximize value for investors and assure the ongoing viability of the companies and their products.

Prior to DSF & Associates, David was founding Partner at JKF Advisors and Bridge Development Partners, corporate advisory firms focusing in healthcare and consumer products.  Previously, he was a Vice President of Robert Fleming & Co., based in New York, where he provided a wide range of M&A, corporate finance, and advisory services to public and privately-held companies on four continents, focusing in life sciences, chemicals, and natural resources sectors. His previous work experience includes two-and-a-half years in the Investment Banking Department at Drexel Burnham Lambert, International Corporate Finance at Nikko Securities Co. Ltd. in Tokyo, and Merger and Acquisitions at Bankers Trust Company in New York.

David holds a BA (History – Honors) from Haverford College and an MBA (Finance) from The Wharton School, University of Pennsylvania.  He also studied at the London School of Economics (Economic & Political History).